Myosin Light Chain Kinase Inhibitor Compounds, Compositions and Related Methods of Use

Daniel Watterson (Inventor)

Research output: Patent

Abstract

Myosin Light Chain Kinase Inhibitor Compounds, Compositions and Related Methods of Use NU 2006-088 Invention Linda J. Van Eldik Heather A Behanna Daniel Martin Watterson Hantamalala Ralay Ranaivo Short Description Development of a new class of small molecule therapeutic candidates with potential to address areas of disease and injury relevant to tissue barrier dysfunction Abstract Northwestern researchers have discovered a new small-molecular inhibitor of myosin light-chain kinase (MLCK) as a potential therapeutic for treating sepsis and associated tissue injuries. They have identified Compound 6, which possesses the requisite molecular properties for bioavailability and demonstrates effective protection against endotoxin-induced vascular leakage and overall tissue injury and death. Compound 6 is a promising therapeutic candidate for acute lung injury and disorders involving tissue barrier dysfunction, including sepsis, lung injury, microvascular leakage, Crohn's disease as well as multi-organ failure. Applications Therapeutics: Small Molecule Advantages Bioavailability Therapeutics for unmet area Publications Behanna HA, Watterson DM, Ranaivo HR (2006) Development of a novel bioavailable inhibitor of the calmodulin-regulated protein kinase MLCK: A lead compound that attenuates vascular leak. Biochimica et Biophysica Acta 1763: 1266-1274. IP Status Issued US Patent No. 7,732,445 Marketing Contact Allan Nader, PhD Invention Manager (p) (847) 491-4456 (e) a-nader@northwestern.edu
Original languageEnglish
Patent number8278305
StatePublished - Sep 23 2010

Fingerprint Dive into the research topics of 'Myosin Light Chain Kinase Inhibitor Compounds, Compositions and Related Methods of Use'. Together they form a unique fingerprint.

  • Cite this